Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INV-1120 |
| Synonyms | |
| Therapy Description |
INV-1120 is an antagonist of the prostaglandin E2 receptor subtype 4 (EP4), and inhibits binding of the prostaglandin E2 to EP4, potentially leading to altered anti-tumor immune response and inhibition of cell proliferation (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INV-1120 | INV1120|INV 1120 | INV-1120 is an antagonist of the prostaglandin E2 receptor subtype 4 (EP4), and inhibits binding of the prostaglandin E2 to EP4, potentially leading to altered anti-tumor immune response and inhibition of cell proliferation (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04443088 | Phase I | INV-1120 | A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors | Active, not recruiting | USA | 0 |